Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Age-Related Macular Degeneration
Interventions
DRUG

ranibizumab

0.5mg intravitreal injection, monthly for 12 months, or until BCVA returns to pre-wet AMD baseline.

Trial Locations (4)

78240

Medical Center Ophthalmology Associates, San Antonio

92093

Shiley Eye Center, UCSD, La Jolla

93103

California Retina Consultants, Santa Barbara

93309

California Retina Consultants, Bakersfield

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

University of California, San Diego

OTHER